SCHEMBL111162

SCHEMBL111162

Cc1cc(C)n(CC(=O)N2CCN(c3ccccc3C(=O)Nc3ccc(C#N)nc3)CC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 3/20 0.54
KCNH2 Q12809 1/20 0.54
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
BRAF P15056 1/20 0.39
KCNQ3 O43525 1/20 0.38
KCNQ2 O43526 1/20 0.38
LMNA P02545 2/20 0.37
PPARG P37231 1/20 0.37
CYP1A2 P05177 2/20 0.37
GAA P10253 2/20 0.36
THRB P10828 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111164 0.90 CXCR3 (0.59) CXCR3KCNH2TSHRSMN1; SMN2KMT2A
SCHEMBL114797 0.88 CXCR3 (0.57) CXCR3KCNH2TSHRSMN1; SMN2KMT2A
SCHEMBL13075874 0.87 CXCR3 (0.56) CXCR3KCNH2TSHRSMN1; SMN2ALDH1A1
SCHEMBL111873 0.87 CXCR3 (0.56) CXCR3KCNH2TSHRSMN1; SMN2KMT2A
SCHEMBL112603 0.87 CXCR3 (0.56) CXCR3KCNH2TSHRSMN1; SMN2MAPT
SCHEMBL109996 0.87 CXCR3 (0.55) CXCR3KCNH2TSHRSMN1; SMN2MAPK1
SCHEMBL111491 0.86 CXCR3 (0.61) CXCR3KCNH2TSHRSMN1; SMN2KMT2A
SCHEMBL111946 0.86 CXCR3 (0.54) CXCR3KCNH2TSHRSMN1; SMN2KMT2A
SCHEMBL112638 0.85 CXCR3 (0.54) CXCR3KCNH2TSHRLMNACYP1A2
SCHEMBL111889 0.85 CXCR3 (0.67) CXCR3KCNH2TSHRSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885KCNH2 1384/4885TSHR 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.